Annals of Pediatric Endocrinology and Metabolism

Korean Society of Pediatric Endocrinology (대한소아내분비학회)
권호 표지
DOI QR코드

DOI QR Code

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes

  • Lee, Seungah (Department of Bioengineering, College of Engineering, and BK21 PLUS Future Biopharmaceutical Human Resources Training and Research Team, Hanyang University) ;
  • Lee, Dong Yun (Department of Bioengineering, College of Engineering, and BK21 PLUS Future Biopharmaceutical Human Resources Training and Research Team, Hanyang University)
  • Received : 2017.03.07
  • Accepted : 2017.03.30
  • Published : 2017.03.30
⟨ Previous Next ⟩

Abstract

The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related conditions by augmenting pancreatic ${\beta}-cell$ insulin secretion and having the low risk of causing hypoglycemia. Because of a very short half-life of GLP-1, many researches have been focused on the development of GLP-1 receptor (GLP-1R) agonists with long half-lives such as exenatide and dulaglutide. Now GLP-1R agonists have a variety of dosing-cycle forms to meet the needs of various patients. In this article, we review the physiological features of GLP-1, the effects of GLP-1 on T2D, the features of several GLP-1R agonists, and the therapeutic effect on T2D.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

Cited by

  1. Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity vol.9, pp.None, 2017, https://doi.org/10.3389/fpsyt.2018.00784
  2. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists vol.24, pp.9, 2017, https://doi.org/10.18553/jmcp.2018.24.9-a.s14
  3. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications vol.24, pp.9, 2018, https://doi.org/10.18553/jmcp.2018.24.9-a.s42
  4. Association Between Exercise and Treatment with Liraglutide in Obese Rats by Cafeteria Diet vol.62, pp.None, 2017, https://doi.org/10.1590/1678-4324-2019180563
  5. GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner vol.68, pp.1, 2017, https://doi.org/10.2337/db18-0317
  6. Anti-inflammatory and pro-healing impacts of exendin-4 treatment in Zucker diabetic rats: Effects on skin wound fibroblasts vol.842, pp.None, 2017, https://doi.org/10.1016/j.ejphar.2018.10.053
  7. Exenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use vol.35, pp.2, 2017, https://doi.org/10.1007/s40267-018-00597-2
  8. Narrative review of the effects of antidiabetic drugs on albuminuria vol.234, pp.5, 2017, https://doi.org/10.1002/jcp.27503
  9. Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients vol.8, pp.11, 2017, https://doi.org/10.2217/cer-2019-0002
  10. The role of Leu260Phe polymorphism of the receptor gene to GLP-1 incretin in the pathogenesis of diabetes type 2 diabetes with obesity vol.22, pp.3, 2017, https://doi.org/10.14341/dm9974
  11. Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease vol.35, pp.6, 2017, https://doi.org/10.1007/s12264-019-00407-3
  12. An overview of the neuroendocrine system in Parkinson’s disease: what is the impact on diagnosis and treatment? vol.20, pp.2, 2017, https://doi.org/10.1080/14737175.2020.1701437
  13. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists vol.9, pp.4, 2017, https://doi.org/10.3390/jcm9040947
  14. Liraglutide treatment and acylcarnitine profiles in Egyptian obese insulin-resistant females vol.891, pp.None, 2021, https://doi.org/10.1016/j.ejphar.2020.173668
  15. GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats vol.4, pp.1, 2017, https://doi.org/10.1021/acsptsci.0c00193
  16. Choline‐Geranate Deep Eutectic Solvent Improves Stability and Half‐Life of Glucagon‐Like Peptide‐1 vol.4, pp.3, 2017, https://doi.org/10.1002/adtp.202000180